Semaglutide vs Saxenda (Liraglutide): Older vs Newer GLP-1

Saxenda (liraglutide) was the first GLP-1 receptor agonist approved specifically for weight management, earning its FDA approval in 2014. Semaglutide, available as Wegovy for weight loss and Ozempic for diabetes, arrived later but quickly became the dominant GLP-1 medication thanks to superior weight loss results and the convenience of weekly dosing. Both medications belong to the same drug class, but important differences in potency, dosing schedule, clinical outcomes, and practical considerations make this comparison worth understanding.

GLP-1 Receptor Agonists: Same Class, Different Generations

Both semaglutide and liraglutide are GLP-1 receptor agonists — they mimic the incretin hormone GLP-1 to reduce appetite, slow gastric emptying, and improve blood sugar regulation. Think of them as two versions of the same type of medication, with semaglutide representing a newer, more refined design.

Liraglutide (Saxenda) shares 97% amino acid homology with native human GLP-1 but has modifications that extend its half-life to approximately 13 hours, enabling once-daily dosing. Semaglutide has further structural modifications, including a fatty acid chain that binds strongly to albumin in the blood, giving it a half-life of approximately 7 days — hence the once-weekly injection schedule.

Efficacy: The Head-to-Head Data

The STEP 8 trial provided the most direct comparison of semaglutide and liraglutide for weight loss. This 68-week randomized, open-label trial compared semaglutide 2.4 mg weekly to liraglutide 3.0 mg daily in adults with obesity or overweight with comorbidities.

The results are striking: semaglutide produced approximately 2.5 times more weight loss than liraglutide. Nearly 71% of semaglutide users lost at least 10% of their body weight, compared to just 26% of liraglutide users. The difference was statistically significant across every measured endpoint.

Dosing and Administration

Semaglutide (Wegovy) Dosing

Semaglutide is injected subcutaneously once per week, on the same day each week, at any time of day, with or without food. The titration schedule is gradual:

• Weeks 1-4: 0.25 mg weekly
• Weeks 5-8: 0.5 mg weekly
• Weeks 9-12: 1.0 mg weekly
• Weeks 13-16: 1.7 mg weekly
• Week 17 onward: 2.4 mg weekly (maintenance dose)

Liraglutide (Saxenda) Dosing

Saxenda is injected subcutaneously once daily, at any time, with or without food. The titration schedule is faster:

• Week 1: 0.6 mg daily
• Week 2: 1.2 mg daily
• Week 3: 1.8 mg daily
• Week 4: 2.4 mg daily
• Week 5 onward: 3.0 mg daily (maintenance dose)

The daily injection requirement of Saxenda is often cited as a disadvantage. However, some patients prefer it because smaller daily doses allow for more granular dose adjustments if side effects arise. With weekly semaglutide, a missed dose means waiting longer before the next opportunity.

Side Effects: Similar Class, Similar Profile

Because both medications work through the same GLP-1 receptor pathway, their side effect profiles overlap considerably. Gastrointestinal issues dominate:

• Nausea: Common with both, reported in roughly 30-40% of semaglutide users and 39% of Saxenda users
• Diarrhea: Approximately 30% (semaglutide) and 21% (Saxenda)
• Vomiting: More common with semaglutide (~24%) vs Saxenda (~16%)
• Constipation: Similar rates (~20-24%) for both
• Injection site reactions: Generally mild with both; daily injections with Saxenda mean more opportunities for localized reactions

Both medications carry similar rare risk warnings, including pancreatitis, gallbladder disease, and a boxed warning about thyroid C-cell tumors based on animal data. Neither should be used in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

In the STEP 8 trial, discontinuation due to adverse events was slightly higher with semaglutide (3.2%) than liraglutide (2.6%), though the difference was not statistically significant.

Beyond Weight Loss: Additional Health Benefits

Both GLP-1 agonists offer metabolic benefits beyond the number on the scale:

• Cardiovascular outcomes: Semaglutide showed a 20% reduction in major adverse cardiovascular events (MACE) in the SELECT trial. Liraglutide demonstrated a 13% MACE reduction in the LEADER trial (though this was in a diabetes population, not weight management).
• Blood sugar control: Both improve HbA1c in patients with diabetes or prediabetes. Semaglutide generally produces greater HbA1c reductions.
• Blood pressure: Both produce modest reductions in systolic blood pressure.
• Lipid profile: Both improve triglycerides and other lipid markers, with semaglutide showing slightly greater improvements.

Cost and Insurance Considerations

Pricing for brand-name versions of both medications is similar:

• Saxenda: Approximately $1,000-$1,400 per month at list price
• Wegovy: Approximately $1,300-$1,400 per month at list price
• Ozempic (if used off-label for weight loss): Approximately $900-$1,000 per month

Insurance coverage can vary significantly between the two. Some plans that cover Saxenda may not yet cover Wegovy, and vice versa. Patients should always check their specific formulary.

For patients paying out of pocket, compounded semaglutide through telehealth providers like Trimi offers a substantially more affordable alternative. There is no widely available compounded liraglutide option, which limits cost-reduction strategies for Saxenda.

Switching from Saxenda to Semaglutide

Many patients currently on Saxenda wonder about switching to semaglutide. The transition is straightforward and commonly done under medical supervision:

• Stop Saxenda on the day you plan to begin semaglutide
• Start semaglutide at the lowest dose (0.25 mg weekly) regardless of your previous Saxenda dose
• Follow the standard semaglutide titration schedule
• No washout period is necessary, though your provider may recommend a brief gap

Patients switching often report improved convenience (weekly vs daily injections) and enhanced weight loss results after reaching therapeutic semaglutide doses. Some GI side effects may recur during the transition as your body adjusts to the new medication.

Who Should Choose Which?

Semaglutide Is Likely the Better Choice If You:

• Want maximum weight loss potential
• Prefer weekly dosing convenience
• Have cardiovascular risk factors (stronger CV benefit data)
• Are starting fresh with GLP-1 therapy
• Can access it through insurance or affordable compounded options

Saxenda May Still Be Worth Considering If You:

• Have insurance that covers Saxenda but not semaglutide
• Prefer daily dosing for more flexible dose adjustments
• Have responded well to Saxenda and are achieving your goals
• Are an adolescent patient (both are approved for ages 12+, but Saxenda has longer pediatric track record)

The Bottom Line

Semaglutide represents a clear advancement over liraglutide (Saxenda) in nearly every measurable dimension: greater weight loss, less frequent dosing, and stronger cardiovascular outcome data. The STEP 8 trial showed semaglutide producing roughly 2.5 times the weight loss of liraglutide in a direct comparison.

That said, Saxenda was groundbreaking when it launched and remains a viable option, particularly when insurance or access favors it. The most important step is working with a healthcare provider to determine which GLP-1 medication aligns with your goals, medical history, and practical circumstances. Learn how Trimi can help you get started with an evidence-based weight loss plan.

Frequently Asked Questions